Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Change in Accured Expenses readings, the most recent being -$9.2 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 260.78% to -$9.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.5 million, a 59.11% decrease, with the full-year FY2025 number at $24.2 million, down 55.13% from a year prior.
  • Change in Accured Expenses hit -$9.2 million in Q1 2026 for Catalyst Pharmaceuticals, down from $5.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $20.0 million in Q3 2024 to a low of -$9.2 million in Q1 2026.
  • Median Change in Accured Expenses over the past 5 years was $8.2 million (2023), compared with a mean of $5.4 million.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 316.77% in 2023 and later soared 449.88% in 2024.
  • Catalyst Pharmaceuticals' Change in Accured Expenses stood at $11.5 million in 2022, then dropped by 28.82% to $8.2 million in 2023, then increased by 8.67% to $8.9 million in 2024, then plummeted by 41.46% to $5.2 million in 2025, then crashed by 276.72% to -$9.2 million in 2026.
  • The last three reported values for Change in Accured Expenses were -$9.2 million (Q1 2026), $5.2 million (Q4 2025), and $13.2 million (Q3 2025) per Business Quant data.